Approximately 701 patients will participate in this study worldwide and it is estimated to be completed in June 2018. This study is currently recruiting participants. Read more.
![[Required]](/wp-content/uploads/2017/04/arrow_curved_right.png){kind=icon}
![[Unlock]](/wp-content/uploads/2017/08/human_box.png "Unlock")
![[Locked]](/wp-content/uploads/2017/02/lock.png "Locked")
Free Dental in Miami-Dade
browardliving.org
To improve and maintain oral health of the medically underserved.
Leave a Reply
Trump: The Art of the Deal, Free and Low-cost Dental in Florida, VSP Individual Vision Plans, HCG Weight Loss Cure Guide, The Book of Psalms, Free Android Apps, Organizing for Social Change, ANORO™ ELLIPTA™, What Happened, by Hillary Rodham Clinton, Maximilian Kolbe: Saint of Auschwitz, Why Pro-Life? Caring for the Unborn and Their Mothers, Georgia Testing Centers, Cavelady Cooking: 50 Fun Recipes, Tai Chi Classes, Adopt a Child, Kindle Wireless Reading Device $189, Patient Assistance Programs, Think BIG, by Donald J. Trump, USB Micro SD Card Adapter, Drive Traffic to Your Website with Amazon, and more!
Over $700 in Grocery Store Coupons, instantly! Look inside ยป
e.g. Free Clinics, Free Dental, Free Magazines, etc.
What is MLN9708?
MLN9708 is an investigational targeted anti-cancer drug given orally. MLN9708 is being studied in multiple myeloma, various hematologic malignancies, and solid tumors.
View CommentWhat is multiple myeloma?
Multiple myeloma is a cancer of plasma cells, a type of white blood cell present in bone marrow. Plasma cells normally make proteins called antibodies to help you fight infections. Read more.
View CommentWhat is the official title of this study?
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Jul 9, 2013 – This study is currently recruiting participants. Verified July 2013 by Millennium Pharmaceuticals, Inc. Sponsor: Millennium Pharmaceuticals, Inc. Identifier: NCT01850524
View Comment